Serum  ||| S:0 E:6 ||| NNP
IL-23  ||| S:6 E:12 ||| NNP
in  ||| S:12 E:15 ||| IN
asthmatic  ||| S:15 E:25 ||| JJ
children  ||| S:25 E:34 ||| NNS
Asthma  ||| S:34 E:41 ||| NNP
is  ||| S:41 E:44 ||| VBZ
characterized  ||| S:44 E:58 ||| VBN
by  ||| S:58 E:61 ||| IN
airway  ||| S:61 E:68 ||| JJ
inflammation  ||| S:68 E:81 ||| NN
that  ||| S:81 E:86 ||| WDT
is  ||| S:86 E:89 ||| VBZ
controlled  ||| S:89 E:100 ||| VBN
by  ||| S:100 E:103 ||| IN
a  ||| S:103 E:105 ||| DT
complex  ||| S:105 E:113 ||| JJ
cytokine  ||| S:113 E:122 ||| JJ
network ||| S:122 E:129 ||| NN
.  ||| S:129 E:131 ||| .
The  ||| S:131 E:135 ||| DT
Th1 ||| S:135 E:138 ||| CD
/ ||| S:138 E:139 ||| CD
Th2  ||| S:139 E:143 ||| CD
imbalance  ||| S:143 E:153 ||| NN
has  ||| S:153 E:157 ||| VBZ
been  ||| S:157 E:162 ||| VBN
well  ||| S:162 E:167 ||| RB
documented  ||| S:167 E:178 ||| VBN
in  ||| S:178 E:181 ||| IN
the  ||| S:181 E:185 ||| DT
pathogenesis  ||| S:185 E:198 ||| NN
of  ||| S:198 E:201 ||| IN
allergic  ||| S:201 E:210 ||| JJ
asthma ||| S:210 E:216 ||| NN
.  ||| S:216 E:218 ||| .
Recently ||| S:218 E:226 ||| RB
,  ||| S:226 E:228 ||| ,
Th17  ||| S:228 E:233 ||| CD
cells  ||| S:233 E:239 ||| NNS
and  ||| S:239 E:243 ||| CC
regulatory  ||| S:243 E:254 ||| JJ
T  ||| S:254 E:256 ||| NN
( ||| S:256 E:257 ||| -LRB-
Treg ||| S:257 E:261 ||| NNP
)  ||| S:261 E:263 ||| -RRB-
cells  ||| S:263 E:269 ||| NNS
have  ||| S:269 E:274 ||| VBP
been  ||| S:274 E:279 ||| VBN
found  ||| S:279 E:285 ||| VBN
to  ||| S:285 E:288 ||| TO
participate  ||| S:288 E:300 ||| VB
in  ||| S:300 E:303 ||| IN
the  ||| S:303 E:307 ||| DT
pathogenesis  ||| S:307 E:320 ||| NN
of  ||| S:320 E:323 ||| IN
allergic  ||| S:323 E:332 ||| JJ
asthma ||| S:332 E:338 ||| NN
.  ||| S:338 E:340 ||| .
This  ||| S:340 E:345 ||| DT
study  ||| S:345 E:351 ||| NN
aimed  ||| S:351 E:357 ||| VBN
at  ||| S:357 E:360 ||| IN
verifying  ||| S:360 E:370 ||| NN
whether  ||| S:370 E:378 ||| IN
anti-inflammatory  ||| S:378 E:396 ||| JJ
treatment  ||| S:396 E:406 ||| NN
could  ||| S:406 E:412 ||| MD
change  ||| S:412 E:419 ||| VB
serum  ||| S:419 E:425 ||| JJ
IL-4 ||| S:425 E:429 ||| NN
,  ||| S:429 E:431 ||| ,
IL-10  ||| S:431 E:437 ||| NNP
and  ||| S:437 E:441 ||| CC
IL-23  ||| S:441 E:447 ||| CD
in  ||| S:447 E:450 ||| IN
asthmatic  ||| S:450 E:460 ||| JJ
children ||| S:460 E:468 ||| NNS
.  ||| S:468 E:470 ||| .
Globally ||| S:470 E:478 ||| RB
,  ||| S:478 E:480 ||| ,
78  ||| S:480 E:483 ||| CD
children  ||| S:483 E:492 ||| NNS
( ||| S:492 E:493 ||| -LRB-
40  ||| S:493 E:496 ||| CD
males  ||| S:496 E:502 ||| NNS
and  ||| S:502 E:506 ||| CC
38  ||| S:506 E:509 ||| CD
females ||| S:509 E:516 ||| NNS
,  ||| S:516 E:518 ||| ,
median  ||| S:518 E:525 ||| JJ
age  ||| S:525 E:529 ||| NN
9.3  ||| S:529 E:533 ||| CD
+-  ||| S:533 E:536 ||| CD
3.7  ||| S:536 E:540 ||| CD
years ||| S:540 E:545 ||| NNS
) ||| S:545 E:546 ||| -RRB-
,  ||| S:546 E:548 ||| ,
with  ||| S:548 E:553 ||| IN
asthma  ||| S:553 E:560 ||| NN
and  ||| S:560 E:564 ||| CC
monosensitized  ||| S:564 E:579 ||| JJ
to  ||| S:579 E:582 ||| TO
house  ||| S:582 E:588 ||| VB
dust  ||| S:588 E:593 ||| NN
mites ||| S:593 E:598 ||| NNS
,  ||| S:598 E:600 ||| ,
were  ||| S:600 E:605 ||| VBD
evaluated ||| S:605 E:614 ||| VBN
.  ||| S:614 E:616 ||| .
Lung  ||| S:616 E:621 ||| NNP
function  ||| S:621 E:630 ||| NN
( ||| S:630 E:631 ||| -LRB-
such  ||| S:631 E:636 ||| JJ
as  ||| S:636 E:639 ||| IN
FEV1 ||| S:639 E:643 ||| CD
)  ||| S:643 E:645 ||| -RRB-
and  ||| S:645 E:649 ||| CC
serum  ||| S:649 E:655 ||| JJ
IL-4 ||| S:655 E:659 ||| NN
,  ||| S:659 E:661 ||| ,
IL-10  ||| S:661 E:667 ||| NNP
and  ||| S:667 E:671 ||| CC
IL-23  ||| S:671 E:677 ||| CD
levels  ||| S:677 E:684 ||| NNS
were  ||| S:684 E:689 ||| VBD
measured  ||| S:689 E:698 ||| VBN
at  ||| S:698 E:701 ||| IN
baseline  ||| S:701 E:710 ||| NN
( ||| S:710 E:711 ||| -LRB-
T0 ||| S:711 E:713 ||| NNP
) ||| S:713 E:714 ||| -RRB-
,  ||| S:714 E:716 ||| ,
after  ||| S:716 E:722 ||| IN
4  ||| S:722 E:724 ||| CD
weeks  ||| S:724 E:730 ||| NNS
( ||| S:730 E:731 ||| -LRB-
T1 ||| S:731 E:733 ||| NNP
)  ||| S:733 E:735 ||| -RRB-
and  ||| S:735 E:739 ||| CC
after  ||| S:739 E:745 ||| IN
12  ||| S:745 E:748 ||| CD
weeks  ||| S:748 E:754 ||| NNS
( ||| S:754 E:755 ||| -LRB-
T2 ||| S:755 E:757 ||| NNP
)  ||| S:757 E:759 ||| -RRB-
of  ||| S:759 E:762 ||| IN
inhaled  ||| S:762 E:770 ||| JJ
corticosteroid  ||| S:770 E:785 ||| NNS
( ||| S:785 E:786 ||| -LRB-
ICS ||| S:786 E:789 ||| NNP
)  ||| S:789 E:791 ||| -RRB-
treatment ||| S:791 E:800 ||| NN
.  ||| S:800 E:802 ||| .
The  ||| S:802 E:806 ||| DT
control  ||| S:806 E:814 ||| NN
group  ||| S:814 E:820 ||| NN
consisted  ||| S:820 E:830 ||| VBD
of  ||| S:830 E:833 ||| IN
40  ||| S:833 E:836 ||| CD
healthy  ||| S:836 E:844 ||| JJ
children  ||| S:844 E:853 ||| NNS
( ||| S:853 E:854 ||| -LRB-
22  ||| S:854 E:857 ||| CD
males  ||| S:857 E:863 ||| NNS
and  ||| S:863 E:867 ||| CC
18  ||| S:867 E:870 ||| CD
females ||| S:870 E:877 ||| NNS
)  ||| S:877 E:879 ||| -RRB-
age  ||| S:879 E:883 ||| NN
matched ||| S:883 E:890 ||| VBD
.  ||| S:890 E:892 ||| .
At  ||| S:892 E:895 ||| IN
baseline ||| S:895 E:903 ||| NN
,  ||| S:903 E:905 ||| ,
IL-4  ||| S:905 E:910 ||| NN
and  ||| S:910 E:914 ||| CC
IL-23  ||| S:914 E:920 ||| CD
levels  ||| S:920 E:927 ||| NNS
were  ||| S:927 E:932 ||| VBD
higher  ||| S:932 E:939 ||| JJR
in  ||| S:939 E:942 ||| IN
severe  ||| S:942 E:949 ||| JJ
asthmatics  ||| S:949 E:960 ||| NN
than  ||| S:960 E:965 ||| IN
in  ||| S:965 E:968 ||| IN
control  ||| S:968 E:976 ||| NN
group  ||| S:976 E:982 ||| NN
( ||| S:982 E:983 ||| -LRB-
p  ||| S:983 E:985 ||| RB
less  ||| S:985 E:990 ||| JJR
than  ||| S:990 E:995 ||| IN
0.001 ||| S:995 E:1000 ||| CD
) ||| S:1000 E:1001 ||| -RRB-
,  ||| S:1001 E:1003 ||| ,
while  ||| S:1003 E:1009 ||| IN
serum  ||| S:1009 E:1015 ||| CD
IL-10  ||| S:1015 E:1021 ||| CD
levels  ||| S:1021 E:1028 ||| NNS
were  ||| S:1028 E:1033 ||| VBD
significantly  ||| S:1033 E:1047 ||| RB
lower  ||| S:1047 E:1053 ||| JJR
in  ||| S:1053 E:1056 ||| IN
group  ||| S:1056 E:1062 ||| NN
of  ||| S:1062 E:1065 ||| IN
asthmatic  ||| S:1065 E:1075 ||| JJ
children  ||| S:1075 E:1084 ||| NNS
as  ||| S:1084 E:1087 ||| RB
compared  ||| S:1087 E:1096 ||| VBN
to  ||| S:1096 E:1099 ||| TO
healthy  ||| S:1099 E:1107 ||| JJ
control  ||| S:1107 E:1115 ||| NN
group  ||| S:1115 E:1121 ||| NN
( ||| S:1121 E:1122 ||| -LRB-
p  ||| S:1122 E:1124 ||| RB
less  ||| S:1124 E:1129 ||| JJR
than  ||| S:1129 E:1134 ||| IN
0.001 ||| S:1134 E:1139 ||| CD
) ||| S:1139 E:1140 ||| -RRB-
.  ||| S:1140 E:1142 ||| .
At  ||| S:1142 E:1145 ||| IN
T2 ||| S:1145 E:1147 ||| NNP
,  ||| S:1147 E:1149 ||| ,
IL-4  ||| S:1149 E:1154 ||| NN
and  ||| S:1154 E:1158 ||| CC
IL-23  ||| S:1158 E:1164 ||| NNP
significantly  ||| S:1164 E:1178 ||| RB
diminished  ||| S:1178 E:1189 ||| VBN
( ||| S:1189 E:1190 ||| -LRB-
p  ||| S:1190 E:1192 ||| RB
less  ||| S:1192 E:1197 ||| JJR
than  ||| S:1197 E:1202 ||| IN
0.001 ||| S:1202 E:1207 ||| CD
) ||| S:1207 E:1208 ||| -RRB-
,  ||| S:1208 E:1210 ||| ,
while  ||| S:1210 E:1216 ||| IN
IL-10  ||| S:1216 E:1222 ||| NNP
significantly  ||| S:1222 E:1236 ||| RB
increased ||| S:1236 E:1245 ||| VBN
.  ||| S:1245 E:1247 ||| .
There  ||| S:1247 E:1253 ||| EX
was  ||| S:1253 E:1257 ||| VBD
significant  ||| S:1257 E:1269 ||| JJ
relationship  ||| S:1269 E:1282 ||| NN
between  ||| S:1282 E:1290 ||| IN
FEV1  ||| S:1290 E:1295 ||| NNP
and  ||| S:1295 E:1299 ||| CC
IL-4 ||| S:1299 E:1303 ||| NN
,  ||| S:1303 E:1305 ||| ,
IL-10  ||| S:1305 E:1311 ||| NNP
and  ||| S:1311 E:1315 ||| CC
IL-23  ||| S:1315 E:1321 ||| CD
at  ||| S:1321 E:1324 ||| IN
T0  ||| S:1324 E:1327 ||| NNP
( ||| S:1327 E:1328 ||| -LRB-
r=-0.784 ||| S:1328 E:1336 ||| NNP
;  ||| S:1336 E:1338 ||| :
r=-0.735  ||| S:1338 E:1347 ||| CD
and  ||| S:1347 E:1351 ||| CC
r=-0.787 ||| S:1351 E:1359 ||| NNP
,  ||| S:1359 E:1361 ||| ,
respectively ||| S:1361 E:1373 ||| RB
) ||| S:1373 E:1374 ||| -RRB-
.  ||| S:1374 E:1376 ||| .
Moreover ||| S:1376 E:1384 ||| RB
,  ||| S:1384 E:1386 ||| ,
there  ||| S:1386 E:1392 ||| EX
were  ||| S:1392 E:1397 ||| VBD
correlations  ||| S:1397 E:1410 ||| VBN
between  ||| S:1410 E:1418 ||| IN
FEV1  ||| S:1418 E:1423 ||| NNP
and  ||| S:1423 E:1427 ||| CC
IL-4 ||| S:1427 E:1431 ||| NN
,  ||| S:1431 E:1433 ||| ,
IL-10  ||| S:1433 E:1439 ||| NNP
and  ||| S:1439 E:1443 ||| CC
IL-23  ||| S:1443 E:1449 ||| CD
in  ||| S:1449 E:1452 ||| IN
patients  ||| S:1452 E:1461 ||| NNS
at  ||| S:1461 E:1464 ||| IN
T1  ||| S:1464 E:1467 ||| NNP
( ||| S:1467 E:1468 ||| -LRB-
r=-0.563 ||| S:1468 E:1476 ||| NNP
;  ||| S:1476 E:1478 ||| :
r=-0.539  ||| S:1478 E:1487 ||| CD
and  ||| S:1487 E:1491 ||| CC
r=-0.583 ||| S:1491 E:1499 ||| NNP
,  ||| S:1499 E:1501 ||| ,
respectively ||| S:1501 E:1513 ||| RB
)  ||| S:1513 E:1515 ||| -RRB-
and  ||| S:1515 E:1519 ||| CC
at  ||| S:1519 E:1522 ||| IN
T2  ||| S:1522 E:1525 ||| NNP
( ||| S:1525 E:1526 ||| -LRB-
r=-0.549 ||| S:1526 E:1534 ||| NNP
;  ||| S:1534 E:1536 ||| :
r=-0.428  ||| S:1536 E:1545 ||| CD
and  ||| S:1545 E:1549 ||| CC
r=-0.393 ||| S:1549 E:1557 ||| NNP
,  ||| S:1557 E:1559 ||| ,
respectively ||| S:1559 E:1571 ||| RB
) ||| S:1571 E:1572 ||| -RRB-
.  ||| S:1572 E:1574 ||| .
The  ||| S:1574 E:1578 ||| DT
present  ||| S:1578 E:1586 ||| JJ
study  ||| S:1586 E:1592 ||| NN
provided  ||| S:1592 E:1601 ||| VBD
evidence  ||| S:1601 E:1610 ||| NN
that ||| S:1610 E:1614 ||| IN
:  ||| S:1614 E:1616 ||| :
i ||| S:1616 E:1617 ||| FW
)  ||| S:1617 E:1619 ||| -RRB-
serum  ||| S:1619 E:1625 ||| VBZ
IL-23  ||| S:1625 E:1631 ||| NNP
was  ||| S:1631 E:1635 ||| VBD
up-regulated  ||| S:1635 E:1648 ||| JJ
also  ||| S:1648 E:1653 ||| RB
in  ||| S:1653 E:1656 ||| IN
asthmatic  ||| S:1656 E:1666 ||| JJ
children ||| S:1666 E:1674 ||| NNS
,  ||| S:1674 E:1676 ||| ,
ii ||| S:1676 E:1678 ||| CD
)  ||| S:1678 E:1680 ||| -RRB-
ICS  ||| S:1680 E:1684 ||| NNP
treatment  ||| S:1684 E:1694 ||| NN
was  ||| S:1694 E:1698 ||| VBD
able  ||| S:1698 E:1703 ||| JJ
of  ||| S:1703 E:1706 ||| IN
reducing  ||| S:1706 E:1715 ||| VBG
IL-23 ||| S:1715 E:1720 ||| NNP
,  ||| S:1720 E:1722 ||| ,
and  ||| S:1722 E:1726 ||| CC
iii ||| S:1726 E:1729 ||| CD
)  ||| S:1729 E:1731 ||| -RRB-
IL-23  ||| S:1731 E:1737 ||| CD
change  ||| S:1737 E:1744 ||| NN
well  ||| S:1744 E:1749 ||| RB
related  ||| S:1749 E:1757 ||| VBN
with  ||| S:1757 E:1762 ||| IN
lung  ||| S:1762 E:1767 ||| NN
function  ||| S:1767 E:1776 ||| NN
improvement ||| S:1776 E:1787 ||| NN
.  ||| S:1787 E:1789 ||| .
Thus ||| S:1789 E:1793 ||| RB
,  ||| S:1793 E:1795 ||| ,
it  ||| S:1795 E:1798 ||| PRP
is  ||| S:1798 E:1801 ||| VBZ
presumable  ||| S:1801 E:1812 ||| VBN
that  ||| S:1812 E:1817 ||| IN
IL-23  ||| S:1817 E:1823 ||| NNP
could  ||| S:1823 E:1829 ||| MD
be  ||| S:1829 E:1832 ||| VB
a  ||| S:1832 E:1834 ||| DT
suitable  ||| S:1834 E:1843 ||| JJ
marker  ||| S:1843 E:1850 ||| NN
of  ||| S:1850 E:1853 ||| IN
allergic  ||| S:1853 E:1862 ||| JJ
inflammation  ||| S:1862 E:1875 ||| NN
in  ||| S:1875 E:1878 ||| IN
asthma ||| S:1878 E:1884 ||| NN
.  ||| S:1884 E:1886 ||| .
